國立虎尾科技大學 |

Practical management of thyroid cancer = a multidisciplinary approach /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Practical management of thyroid cancer/ edited by Ujjal K. Mallick, Clive Harmer.
其他題名:	a multidisciplinary approach /
其他作者:	Harmer, Clive.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	xiv, 399 p. :ill., digital ; : 24 cm.;
Contained By:	Springer Nature eBook
標題:	Pathology. -
電子資源:	https://doi.org/10.1007/978-3-031-38605-3
ISBN:	9783031386053

Practical management of thyroid cancer = a multidisciplinary approach /
Practical management of thyroid cancera multidisciplinary approach /[electronic resource] :edited by Ujjal K. Mallick, Clive Harmer. - Third edition. - Cham :Springer International Publishing :2023. - xiv, 399 p. :ill., digital ;24 cm.

1. Pragmatism, Precision Oncology, International Partnership for Research and Quality-The New Paradigm for Thyroid Cancer -- Section I. Multidisciplinary Approach to Management of Thyroid Cancer -- 2. The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations -- 3. The 2015 American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Key Recommendations -- 4. Thyroid Cancer: One Doctor-Patient Partnership -The Newcastle Butterfly Model -- Section II. The Diagnosis of Thyroid Cancer -- 5. Molecular Diagnosis of Thyroid Nodules -- 6. Ultrasonography in Diagnosis and Management of Thyroid Cancer -Current International Recommendations -- Section III. Initial Thyroid Surgery -- 7. The 21st Century Endocrine Surgeon -- 8. Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer -- 9. Advances in Thyroid Surgery -- Section IV. Non surgical Management of Differentiated Thyroid Cancer -- 10. Risk Stratification and Current Management of Low Risk Thyroid Cancer -- 11. Management of Low risk Papillary Thyroid Carcinomo and Papillary Cancer and Microcarcinoma-the Japanese experience -- 12. Radioiodine Ablation - Current Status -- 13. Dosimetric Approaches - Current Concepts -- 14. External Radiation in Differentiated Thyroid Cancer in the era of IMRT and modern radiation planning techniques -- Section V. Follow up and Longterm Management of Differentiated Thyroid Cancer -- 15. Thyroglobulin -- 16. Management of Post-Operative Hypocalcemia -- 17. Radioiodine Refractory Thyroid Cancer -- Section VI. Medullary Thyroid Carcinoma -- 18. Medullary Thyroid Cancer :Surgical Management -- 19. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management -- 20. Familial Non-Medullary Thyroid Cancer -- Section VII. Thyroid Cancer in Children -- 21. Pediatric Differentiated Thyroid Carcinoma -- Section VIII. Aggressive Thyroid Cancers -- 22. Anaplastic Thyroid Cancer -- 23. Palliative care -- Section IX. Future Developments and Directions for Research in Thyroid Cancer -- 24. Translational Research and Genomics Driven Trials in Thyroid Cancer -- 25. Thyroid Cancer Trials -- 26. The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer -- 27. Survivorship: The Role of the Clinical Psychologist and the Clinical Nurse Specialist in Thyroid Cancer Care.

Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic. The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRK gene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed. The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well. This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.

ISBN: 9783031386053

Standard No.: 10.1007/978-3-031-38605-3doiSubjects--Topical Terms:

668553
Pathology.

LC Class. No.: RC280.T6 / P73 2023

Dewey Class. No.: 616.9944406

Practical management of thyroid cancer = a multidisciplinary approach /
LDR:05329nam a2200337 a 4500 001 1120956
003 DE-He213
005 20240229120214.0
006 m d
007 cr nn 008maaau
008 240612s2023 sz s 0 eng d
020 $a 9783031386053 $q (electronic bk.)
020 $a 9783031386046 $q (paper)
024 7 $a 10.1007/978-3-031-38605-3 $2 doi
035 $a 978-3-031-38605-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.T6 $b P73 2023
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.9944406 $2 23
090 $a RC280.T6 $b P895 2023
245 0 0 $a Practical management of thyroid cancer $h [electronic resource] : $b a multidisciplinary approach / $c edited by Ujjal K. Mallick, Clive Harmer.
250 $a Third edition.
260 $a Cham : $c 2023. $b Springer International Publishing : $b Imprint: Springer,
300 $a xiv, 399 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. Pragmatism, Precision Oncology, International Partnership for Research and Quality-The New Paradigm for Thyroid Cancer -- Section I. Multidisciplinary Approach to Management of Thyroid Cancer -- 2. The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations -- 3. The 2015 American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Key Recommendations -- 4. Thyroid Cancer: One Doctor-Patient Partnership -The Newcastle Butterfly Model -- Section II. The Diagnosis of Thyroid Cancer -- 5. Molecular Diagnosis of Thyroid Nodules -- 6. Ultrasonography in Diagnosis and Management of Thyroid Cancer -Current International Recommendations -- Section III. Initial Thyroid Surgery -- 7. The 21st Century Endocrine Surgeon -- 8. Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer -- 9. Advances in Thyroid Surgery -- Section IV. Non surgical Management of Differentiated Thyroid Cancer -- 10. Risk Stratification and Current Management of Low Risk Thyroid Cancer -- 11. Management of Low risk Papillary Thyroid Carcinomo and Papillary Cancer and Microcarcinoma-the Japanese experience -- 12. Radioiodine Ablation - Current Status -- 13. Dosimetric Approaches - Current Concepts -- 14. External Radiation in Differentiated Thyroid Cancer in the era of IMRT and modern radiation planning techniques -- Section V. Follow up and Longterm Management of Differentiated Thyroid Cancer -- 15. Thyroglobulin -- 16. Management of Post-Operative Hypocalcemia -- 17. Radioiodine Refractory Thyroid Cancer -- Section VI. Medullary Thyroid Carcinoma -- 18. Medullary Thyroid Cancer :Surgical Management -- 19. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management -- 20. Familial Non-Medullary Thyroid Cancer -- Section VII. Thyroid Cancer in Children -- 21. Pediatric Differentiated Thyroid Carcinoma -- Section VIII. Aggressive Thyroid Cancers -- 22. Anaplastic Thyroid Cancer -- 23. Palliative care -- Section IX. Future Developments and Directions for Research in Thyroid Cancer -- 24. Translational Research and Genomics Driven Trials in Thyroid Cancer -- 25. Thyroid Cancer Trials -- 26. The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer -- 27. Survivorship: The Role of the Clinical Psychologist and the Clinical Nurse Specialist in Thyroid Cancer Care.
520 $a Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic. The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRK gene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed. The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well. This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
650 2 4 $a Pathology. $3 668553
650 2 4 $a Primary Care Medicine. $3 673694
650 2 4 $a Endocrinology. $3 645497
650 2 4 $a Surgery. $3 644132
650 1 4 $a Oncology. $3 593951
650 0 $a Thyroid gland. $3 1436578
650 0 $a Health care teams. $3 1142817
650 0 $a Thyroid gland $x Cancer $x Treatment. $3 788567
650 0 $a Thyroid gland $x Cancer. $3 674084
700 1 $a Harmer, Clive. $3 1209650
700 1 $a Mallick, Ujjal K. $3 1209649
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-38605-3
950 $a Medicine (SpringerNature-11650)